Related Experiment Videos
Hypertrophic cardiomyopathy--therapy with slow channel inhibiting agents
Insights
Slow channel inhibiting agents, like verapamil, effectively relieve hypertrophic cardiomyopathy symptoms in most patients. These agents improve exercise capacity and cardiac function, possibly by enhancing diastolic function.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Hypertrophic cardiomyopathy (HCM) presents with debilitating symptoms like dyspnea and chest pain.
- Left ventricular outflow obstruction is common but not always present in symptomatic HCM.
- The precise mechanisms underlying symptomatic relief in HCM remain incompletely understood.
Purpose of the Study:
- To evaluate the efficacy of slow channel inhibiting agents in managing symptomatic hypertrophic cardiomyopathy.
- To explore the impact of these agents on exercise hemodynamics and cardiac performance.
- To investigate potential mechanisms, such as diastolic function, contributing to symptom improvement.
Main Methods:
- Retrospective analysis of patients with hypertrophic cardiomyopathy treated with slow channel inhibiting agents.
- Assessment of symptom relief (dyspnea, chest pain, syncope).
- Evaluation of exercise hemodynamics, exercise tolerance, and left ventricular function (systolic and diastolic).
Main Results:
- Over 70% of patients experienced significant symptom relief, irrespective of left ventricular outflow obstruction.
- Improvements were noted in exercise hemodynamics and exercise tolerance.
- Left ventricular systolic function generally remained unchanged, but diastolic function appeared to improve.
Conclusions:
- Slow channel inhibiting agents provide substantial symptomatic benefit in a majority of hypertrophic cardiomyopathy patients.
- Improved left ventricular diastolic function may be a key mechanism for symptom relief.
- Further research is needed to clarify the long-term effects on arrhythmias, sudden death, and overall prognosis.
Abstract:
Slow channel inhibiting agents, particularly verapamil, appear to produce beneficial effects in relieving symptoms of dyspnea, chest pain, and syncope or presyncope in over 70% of patients with hypertrophic cardiomyopathy. Symptomatic relief occurs in patients with and without left ventricular outflow obstruction. Exercise hemodynamics, exercise tolerance, and cardiac performance during exercise tend to improve. The mechanisms for this symptomatic improvement, however, are not fully explained. Relief of symptoms is observed irrespective of any changes in the resting or provocable left ventricular outflow gradient. Similarly, changes in left ventricular systolic function, which in general remains unaffected, cannot be the basis for the beneficial response. Slow channel inhibiting agents, however, appear to improve left ventricular diastolic function, the mechanism of which is yet to be elucidated. Nevertheless, improved left ventricular diastolic function may provide an explanation for the relief of some symptoms in patients with hypertrophic cardiomyopathy. The influence of therapy with slow channel inhibiting agents on arrhythmias, sudden death, and on long-term prognosis of patients with hypertrophic cardiomyopathy remains uncertain at the present time and should be the subject of future investigations.